Testing the efficacy of these and additional drug candidates, such as those shown to inhibit oncogenic KRAS and HIF pathways in a colorectal cancer screen (Bousquet et al., 2016), in treating oncogenic RAS in model systems like our fly are urgently needed to identify valuable treatment options in the clinic. The gene discussed is KRAS; the disease is colorectal cancer.